IRIX
NASDAQIRIDEX Corporation
Price$1.13-0.18 (-13.46%)
2026-03-092026-06-10
News · 26 weeks44+233%
2025-12-142026-06-07
Mix2090d
- SEC Filings8(40%)
- Insider6(30%)
- Earnings3(15%)
- Other3(15%)
Latest news
25 items- PRIridex to Present at the Planet MicroCap Las Vegas 2026 ConferenceMOUNTAIN VIEW, Calif., June 09, 2026 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ:IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced plans to participate in the upcoming Planet MicroCap Las Vegas 2026 Conference. Management is scheduled to present on Wednesday, June 17 at 4:00 pm PT. Interested parties may access a live and archived webcast of the presentation on the "Event Calendar" page of the "Investors" section of the company's website at www.IRIDEX.com. About Iridex Corporation Iridex Corporation is a worldwide leader in developing,
- INSIDERChief Financial Officer Dizon Romeo R bought $2,688 worth of shares (2,400 units at $1.12), increasing direct ownership by 2% to 133,325 units (SEC Form 4)4 - IRIDEX CORP (0001006045) (Issuer)
- INSIDERChief Financial Officer Dizon Romeo R bought $2,899 worth of shares (2,521 units at $1.15), increasing direct ownership by 2% to 130,925 units (SEC Form 4)4 - IRIDEX CORP (0001006045) (Issuer)
- INSIDERChief Financial Officer Dizon Romeo R bought $2,808 worth of shares (2,400 units at $1.17), increasing direct ownership by 2% to 128,404 units (SEC Form 4)4 - IRIDEX CORP (0001006045) (Issuer)
- SECSEC Form SD filed by IRIDEX CorporationSD - IRIDEX CORP (0001006045) (Filer)
- INSIDERPresident and CEO Mercer Patrick covered exercise/tax liability with 19,233 shares, decreasing direct ownership by 5% to 372,774 units (SEC Form 4)4 - IRIDEX CORP (0001006045) (Issuer)
- INSIDERChief Financial Officer Dizon Romeo R bought $5,004 worth of shares (5,004 units at $1.00), increasing direct ownership by 4% to 126,004 units (SEC Form 4)4 - IRIDEX CORP (0001006045) (Issuer)
- SECSEC Form 10-Q filed by IRIDEX Corporation10-Q - IRIDEX CORP (0001006045) (Filer)
- SECIRIDEX Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - IRIDEX CORP (0001006045) (Filer)
- PRIridex Reports First Quarter 2026 Financial ResultsMOUNTAIN VIEW, Calif., May 19, 2026 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ:IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today reported financial results for the first quarter ended April 4, 2026. First Quarter 2026 Financial Highlights Generated total revenue of $11.8 million, compared to $11.9 million in the prior year periodCyclo G6® product family revenue was $3.6 million, representing growth of 14% year-over-year compared to $3.2 million in the prior year period Sold 15,500 Cyclo G6 probes compared to 13,900 in the prior year periodSold 24 Cy
- PRIridex to Report First Quarter 2026 Financial Results on May 19, 2026MOUNTAIN VIEW, Calif., May 05, 2026 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ:IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and accessories for the treatment of glaucoma and retinal diseases, today announced plans to release financial results for the first quarter 2026 and provide a business update after the close of trading on May 19, 2026. The Company's management team will host a corresponding conference call beginning at 2:00 p.m. PT / 5:00 p.m. ET. Investors interested in listening to the conference call may do so by dialing +1-646-307-1963 from the US or +1-800-715-9871 internationally and providing Conference ID: 93
- SECSEC Form DEFA14A filed by IRIDEX CorporationDEFA14A - IRIDEX CORP (0001006045) (Filer)
- SECSEC Form DEF 14A filed by IRIDEX CorporationDEF 14A - IRIDEX CORP (0001006045) (Filer)
- PRIridex Announces New Partnership with EyeProGPO to Expand Member Access to Retina Laser TechnologyMOUNTAIN VIEW, Calif., April 07, 2026 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ:IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and accessories for the treatment of glaucoma and retinal diseases, today announced a new partnership with EyeProGPO, an ophthalmology-focused group purchasing organization serving ophthalmology practices, ambulatory surgery centers (ASC), and hospitals across the United States. Through this partnership, the 1,800 plus EyeProGPO members can receive preferred pricing on the Iridex PASCAL® laser platform, IQ 532® and IQ 577® lasers, and the OcuLight® TX laser, helping practices, ASCs, and hospitals im
- SECAmendment: SEC Form D/A filed by IRIDEX CorporationD/A - IRIDEX CORP (0001006045) (Filer)
- INSIDERSEC Form 4 filed by Novel Inspiration International Co., Ltd.4 - IRIDEX CORP (0001006045) (Issuer)
- SECSEC Form 10-K filed by IRIDEX Corporation10-K - IRIDEX CORP (0001006045) (Filer)
- SECIRIDEX Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - IRIDEX CORP (0001006045) (Filer)
- PRIridex Reports Fourth Quarter and Full Year 2025 Financial ResultsMOUNTAIN VIEW, Calif., March 26, 2026 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ:IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today reported financial results for the fourth quarter and full year ended January 3, 2026. Fourth Quarter 2025 Financial Highlights Generated total revenue of $14.7 million, representing growth of 16% year-over-year compared to $12.7 million in the prior year quarterCyclo G6® product family revenue was $3.8 million, representing growth of 15% year-over-year compared to $3.3 million in the prior year quarter Sold 15,900 Cycl
- SECIRIDEX Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits8-K - IRIDEX CORP (0001006045) (Filer)
- PRIridex to Report Fourth Quarter and Full Year 2025 Financial Results on March 26, 2026MOUNTAIN VIEW, Calif., March 12, 2026 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ:IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced plans to release financial results for the fourth quarter and full year 2025 and provide a business update after the close of trading on March 26, 2026. The Company's management team will host a corresponding conference call beginning at 2:00 p.m. PT / 5:00 p.m. ET. Investors interested in listening to the conference call may do so by dialing +1-646-307-1963 from the US or +1-800-715-9871 internationally and pro
- INSIDERChief Financial Officer Dizon Romeo R bought $1,399 worth of shares (1,110 units at $1.26), increasing direct ownership by 0.93% to 121,000 units (SEC Form 4)4 - IRIDEX CORP (0001006045) (Issuer)
- INSIDERChief Financial Officer Dizon Romeo R bought $2,942 worth of shares (2,200 units at $1.34), increasing direct ownership by 2% to 119,890 units (SEC Form 4)4 - IRIDEX CORP (0001006045) (Issuer)
- INSIDERChief Financial Officer Dizon Romeo R bought $2,145 worth of shares (1,500 units at $1.43), increasing direct ownership by 1% to 117,690 units (SEC Form 4)4 - IRIDEX CORP (0001006045) (Issuer)
- INSIDERChief Financial Officer Dizon Romeo R bought $1,460 worth of shares (1,000 units at $1.46), increasing direct ownership by 0.87% to 116,190 units (SEC Form 4)4 - IRIDEX CORP (0001006045) (Issuer)
IRIX FAQ
6 questionsWhat does IRIDEX Corporation do?
IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser photocoagulation systems, which are used for the treatment of diabetic macular edema and other retinal diseases; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic...Where does IRIX stock trade?
IRIDEX Corporation (IRIX) is listed on NASDAQ.What sector and industry is IRIX in?
IRIDEX Corporation operates in the Health Care sector, Biotechnology: Electromedical & Electrotherapeutic Apparatus industry.When did IRIDEX Corporation go public?
IRIDEX Corporation (IRIX) completed its IPO in 1996.What companies are similar to IRIX?
Notable peers in the same industry include MDT (Medtronic plc.), MASI (Masimo Corporation), SEAS (SeaWorld Entertainment Inc.), LIVN (LivaNova PLC), ITGR (Integer Holdings Corporation). Compare IRIX side-by-side with any of them on Quantisnow.How can I track IRIX on Quantisnow?
Quantisnow aggregates IRIDEX Corporation's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow IRIX to receive live email and push alerts on every new disclosure.